by Cal Strode | Jan 28, 2026
This year marks the fourth consecutive time I’ve covered the Alliance for Regenerative Medicine’s (ARM) State of the Industry briefing for Signals, and I’ve enjoyed tracking how the cell and gene therapy sector has evolved in real time. In 2023 and 2024, the briefings...
by Stacey Johnson | Jan 9, 2026
It’s that time of year when we look back at what was popular on Signals over the past 12 months, according to views. I am always curious to see what you are reading and perhaps you are as well? As we head into our 14th year of publishing Signals, I’m very aware of all...
by Laya Kiani | Oct 22, 2025
Are you an early-stage startup founder looking for funding options without giving up equity? If so, non-dilutive funding may be the solution you need. It allows startups to advance research, build credibility and move closer to commercialization while maintaining full...
by CCRM Australia | Oct 1, 2025
Silvio Tiziani, MBA, GAICD, is the CEO of CCRM Australia, leading efforts to bridge the gap between research and industry in regenerative medicine. With extensive experience across academia, health, and industry, he has successfully developed strategic partnerships,...
by Lyla El-Fayomi | Jul 17, 2025
The volume of clinical updates I encounter every month is steadily but very noticeably growing month over month! There are lots to get through, so in this rapid-fire edition of RMNU🔬, you’ll find short summaries on all the biggest headlines of the summer’s first half....
Comments